Dupilumab versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison.
Saved in:
| Title: | Dupilumab versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison. |
|---|---|
| Authors: | Ständer S; Section Pruritus Medicine, Department of Dermatology and Center for Chronic Pruritus, University Hospital Münster, Münster, Germany., Pinter A; Goethe-University Frankfurt Am Main, Frankfurt Am Main, Germany., Hougeir FG; Southeast Research Specialists, Douglasville, GA, USA., Guyot P; Sanofi, Gentilly, France., Xu Y; Regeneron Pharmaceuticals Inc, Tarrytown, NY, USA., Praestgaard AH; Sanofi, Cambridge, MA, USA., Freemantle N; Institute of Clinical Trials and Methodology, University College London, London, UK., Rossi AB; Sanofi, Cambridge, MA, USA., Bégo-Le-Bagousse G; Sanofi, Gentilly, France., Wang Z; Regeneron Pharmaceuticals Inc, Tarrytown, NY, USA., Noonan K; Sanofi, Cambridge, MA, USA., Bastian M; Sanofi, Frankfurt, Germany. mike.bastian@sanofi.com. |
| Source: | Dermatology and therapy [Dermatol Ther (Heidelb)] 2025 Sep; Vol. 15 (9), pp. 2537-2551. Date of Electronic Publication: 2025 Jul 11. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Healthcare Communications Country of Publication: Switzerland NLM ID: 101590450 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2193-8210 (Print) NLM ISO Abbreviation: Dermatol Ther (Heidelb) Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2193-8210 |
|---|---|
| DOI: | 10.1007/s13555-025-01479-y |
